CAR T-cell therapy combined with autologous hematopoietic cell transplantation in patients with refractory/relapsed Burkitt Lymphoma

IF 3.2 4区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Current Research in Translational Medicine Pub Date : 2024-10-23 DOI:10.1016/j.retram.2024.103477

Yifan Liu , Gangfeng Xiao , Yang Liu , Sanfang Tu , Bin Xue , Yadi Zhong , Cailu Zhang , Lili Zhou , Shiguang Ye , Yan Lu , Bing Xiu , Wenjun Zhang , Yi Ding , Jianfei Fu , Ping Li , Liang Huang , Xiu Luo , Aibin Liang

{"title":"CAR T-cell therapy combined with autologous hematopoietic cell transplantation in patients with refractory/relapsed Burkitt Lymphoma","authors":"Yifan Liu , Gangfeng Xiao , Yang Liu , Sanfang Tu , Bin Xue , Yadi Zhong , Cailu Zhang , Lili Zhou , Shiguang Ye , Yan Lu , Bing Xiu , Wenjun Zhang , Yi Ding , Jianfei Fu , Ping Li , Liang Huang , Xiu Luo , Aibin Liang","doi":"10.1016/j.retram.2024.103477","DOIUrl":null,"url":null,"abstract":"<div><div>Burkitt lymphoma (BL) is a highly aggressive type of non-Hodgkin lymphomas that have a high likelihood of relapse and are highly refractory to initial treatment. While high-intensity chemotherapy has improved the outcomes, many adult patients still experience treatment failure, and effective salvage therapies are limited. This study retrospectively analyzed the outcomes of 21 relapsed or refractory (R/R) adult BL patients treated with chimeric antigen receptor T-cell (CAR-T) therapy, combined or not with hematopoietic cell transplantation (HCT), across four Chinese hospitals. Patients were grouped based on treatment strategies: autologous HCT followed by CAR T-cell therapy (auto-HCT+CART group, <em>n</em> = 8), and CAR T-cell therapy alone (CART group, <em>n</em> = 13). The auto-HCT+CART group demonstrated superior outcomes, with an overall response rate (ORR) of 87.5 % and significantly higher 1-year overall survival (OS) and progression-free survival (PFS) rates compared to the CART group (<em>p</em> = 0.014 and <em>p</em> = 0.045, respectively). These findings suggest that combining auto-HCT with CAR-T therapy may enhance long-term disease control in R/R BL patients. These encouraging results highlight the need for further prospective studies to validate our data.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 1","pages":"Article 103477"},"PeriodicalIF":3.2000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452318624000394","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Burkitt lymphoma (BL) is a highly aggressive type of non-Hodgkin lymphomas that have a high likelihood of relapse and are highly refractory to initial treatment. While high-intensity chemotherapy has improved the outcomes, many adult patients still experience treatment failure, and effective salvage therapies are limited. This study retrospectively analyzed the outcomes of 21 relapsed or refractory (R/R) adult BL patients treated with chimeric antigen receptor T-cell (CAR-T) therapy, combined or not with hematopoietic cell transplantation (HCT), across four Chinese hospitals. Patients were grouped based on treatment strategies: autologous HCT followed by CAR T-cell therapy (auto-HCT+CART group, n = 8), and CAR T-cell therapy alone (CART group, n = 13). The auto-HCT+CART group demonstrated superior outcomes, with an overall response rate (ORR) of 87.5 % and significantly higher 1-year overall survival (OS) and progression-free survival (PFS) rates compared to the CART group (p = 0.014 and p = 0.045, respectively). These findings suggest that combining auto-HCT with CAR-T therapy may enhance long-term disease control in R/R BL patients. These encouraging results highlight the need for further prospective studies to validate our data.

查看原文本刊更多论文

CAR T 细胞疗法联合自体造血细胞移植治疗难治性/复发性伯基特淋巴瘤患者

伯基特淋巴瘤（BL）是一种侵袭性很强的非霍奇金淋巴瘤，复发的可能性很高，而且对初始治疗非常难治。虽然高强度化疗改善了治疗效果，但许多成人患者仍会出现治疗失败，有效的挽救疗法也很有限。本研究回顾性分析了中国四家医院的21名复发或难治（R/R）成人BL患者接受嵌合抗原受体T细胞（CAR-T）疗法（无论是否联合造血细胞移植（HCT））治疗的结果。根据治疗策略对患者进行分组：自体造血干细胞移植后进行CAR T细胞治疗（自体造血干细胞移植+CART组，n = 8），以及单独进行CAR T细胞治疗（CART组，n = 13）。与CART组相比，自体血细胞移植+CART组的疗效更优，总反应率（ORR）为87.5%，1年总生存率（OS）和无进展生存率（PFS）明显更高（分别为p = 0.014和p = 0.045）。这些研究结果表明，将自体血细胞移植与CAR-T疗法相结合可提高R/R BL患者的长期疾病控制率。这些令人鼓舞的结果强调了进一步开展前瞻性研究以验证我们的数据的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Research in Translational Medicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology

CiteScore

7.00

自引率

4.90%

发文量

审稿时长

45 days

期刊介绍： Current Research in Translational Medicine is a peer-reviewed journal, publishing worldwide clinical and basic research in the field of hematology, immunology, infectiology, hematopoietic cell transplantation, and cellular and gene therapy. The journal considers for publication English-language editorials, original articles, reviews, and short reports including case-reports. Contributions are intended to draw attention to experimental medicine and translational research. Current Research in Translational Medicine periodically publishes thematic issues and is indexed in all major international databases (2017 Impact Factor is 1.9). Core areas covered in Current Research in Translational Medicine are: Hematology, Immunology, Infectiology, Hematopoietic, Cell Transplantation, Cellular and Gene Therapy.